(function(){var loadHandler=window['sl_{656BC694-C0A1-4D3A-883A-292145561588}'];loadHandler&&loadHandler(10, '<div id="spr0_3a3be9c"><div id="spr1_3a3be9c" class="kern slide"><img id="img0_3a3be9c" src="data/img5.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/><div id="svg6_3a3be9c" style="left:49.06px;top:94.123px;"><svg width="1182" height="3" viewBox="-1.333 -0.667 1182 3"><g fill="#c2b6ab" stroke="none"><path stroke="#c2b6ab" stroke-width="1.333" stroke-linecap="butt" transform="translate(-50.393677,-94.789497)" d="M50.394,95.456 H1229.606"/></g></svg></div><div id="svg9_3a3be9c" style="left:49.06px;top:94.123px;"><svg width="1182" height="3" viewBox="-1.333 -0.667 1182 3"><g fill="#cdd7dc" stroke="none"><path stroke="#cdd7dc" stroke-width="1.333" stroke-linecap="butt" transform="translate(-50.393677,-94.789497)" d="M50.394,95.456 H1229.606"/></g></svg></div></div><div id="spr2_3a3be9c" class="kern slide"><div id="spr3_3a3be9c" style="left:50.394px;top:18.898px;"><div style="width:0px;"><span id="txt0_3a3be9c" data-width="66.250000" style="top:-0.696px;">Aim</span></div></div><div id="spr4_3a3be9c" style="left:50.394px;top:114.354px;"><div style="width:0px;"><span id="txt1_3a3be9c" data-width="1143.515625" style="top:4.347px;">Evaluate the cost-effectiveness of upfront DPYD testing for patients with metastatic breast cancer</span></div><div style="width:0px;"><span id="txt2_3a3be9c" data-width="771.992188" style="top:40.177px;">prescribed capecitabine/5FU from the UK healthcare perspective.</span></div></div><div id="spr5_3a3be9c" style="left:1128.819px;top:682.205px;"><div style="width:0px;"><span id="txt3_3a3be9c" class="nokern" data-width="11.458333" style="left:89.433px;top:0.686px;">11</span></div></div></div></div>', '{"s":[]}');})();